These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29507316)

  • 1. LPS-primed CD11b
    Niu S; Paluszynski J; Bian Z; Shi L; Kidder K; Liu Y
    Sci Rep; 2018 Mar; 8(1):3994. PubMed ID: 29507316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse model for hemolytic uremic syndrome induced by outer membrane vesicles of Escherichia coli O157:H7.
    Kim SH; Lee YH; Lee SH; Lee SR; Huh JW; Kim SU; Chang KT
    FEMS Immunol Med Microbiol; 2011 Dec; 63(3):427-34. PubMed ID: 22029600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diet-induced obesity precipitates kidney dysfunction and alters inflammatory mediators in mice treated with Shiga Toxin 2.
    Harrison LM; Gaines DW; Babu US; Balan KV; Reimschuessel R; Do AB; Pereira MR; Bigley EC; Ferguson M; Mehta A; Williams KM
    Microb Pathog; 2018 Oct; 123():250-258. PubMed ID: 30016681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model.
    Palermo MS; Alves Rosa MF; Van Rooijen N; Isturiz MA
    Clin Exp Immunol; 1999 Jun; 116(3):462-7. PubMed ID: 10361235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease.
    Keepers TR; Psotka MA; Gross LK; Obrig TG
    J Am Soc Nephrol; 2006 Dec; 17(12):3404-14. PubMed ID: 17082244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and characterization of circulating microvesicles containing Shiga toxin type 2 in a rat model of Hemolytic Uremic Syndrome.
    Sacerdoti F; Gomez FD; Jancic C; Lombardo T; Pascuale CA; Moretton MA; Chiappetta DA; Ibarra C; Amaral MM
    Toxicon; 2023 Dec; 236():107349. PubMed ID: 37979924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil Extracellular Traps Induced by Shiga Toxin and Lipopolysaccharide-Treated Platelets Exacerbate Endothelial Cell Damage.
    Landoni VI; Pittaluga JR; Carestia A; Castillo LA; Nebel MC; Martire-Greco D; Birnberg-Weiss F; Schattner M; Schierloh P; Fernández GC
    Front Cell Infect Microbiol; 2022; 12():897019. PubMed ID: 35811684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of neutrophils in the murine model of haemolytic uraemic syndrome: mechanisms involved in Shiga toxin type 2-induced neutrophilia.
    Fernandez GC; Lopez MF; Gomez SA; Ramos MV; Bentancor LV; Fernandez-Brando RJ; Landoni VI; Dran GI; Meiss R; Isturiz MA; Palermo MS
    Clin Exp Immunol; 2006 Oct; 146(1):76-84. PubMed ID: 16968401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Mouse Model of Shiga Toxin 2 (Stx2) Intoxication for Testing Therapeutic Agents Against Hemolytic Uremic Syndrome (HUS).
    Mejias MP; Fernandez-Brando RJ; Ramos MV; Abrey-Recalde MJ; Zotta E; Meiss R; Palermo MS
    Curr Pharm Des; 2016; 22(34):5294-5299. PubMed ID: 27356777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.
    Siegler RL; Obrig TG; Pysher TJ; Tesh VL; Denkers ND; Taylor FB
    Pediatr Nephrol; 2003 Feb; 18(2):92-6. PubMed ID: 12579394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.
    Sauter KA; Melton-Celsa AR; Larkin K; Troxell ML; O'Brien AD; Magun BE
    Infect Immun; 2008 Oct; 76(10):4469-78. PubMed ID: 18694970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
    Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
    J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profile and injury sites in mice treated with Shiga toxin 2 and lipopolysaccharide as a Shiga toxin-associated hemolytic uremic syndrome model.
    Kume Y; Go H; Maeda R; Suyama K; Mori T; Kawasaki Y; Hashimoto K; Hosoya M
    Physiol Genomics; 2022 May; 54(5):153-165. PubMed ID: 35384732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.
    Locatelli M; Buelli S; Pezzotta A; Corna D; Perico L; Tomasoni S; Rottoli D; Rizzo P; Conti D; Thurman JM; Remuzzi G; Zoja C; Morigi M
    J Am Soc Nephrol; 2014 Aug; 25(8):1786-98. PubMed ID: 24578132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality.
    Palermo M; Alves-Rosa F; Rubel C; Fernández GC; Fernández-Alonso G; Alberto F; Rivas M; Isturiz M
    Clin Exp Immunol; 2000 Jan; 119(1):77-83. PubMed ID: 10606967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter sequence of Shiga toxin 2 (Stx2) is recognized in vivo, leading to production of biologically active Stx2.
    Bentancor LV; Mejías MP; Pinto A; Bilen MF; Meiss R; Rodriguez-Galán MC; Baez N; Pedrotti LP; Goldstein J; Ghiringhelli PD; Palermo MS
    mBio; 2013 Oct; 4(5):e00501-13. PubMed ID: 24085779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Particulate Shiga Toxin 2 in Blood is Associated to the Development of Hemolytic Uremic Syndrome in Children.
    Brigotti M; He X; Carnicelli D; Arfilli V; Porcellini E; Galassi E; Tazzari PL; Ricci F; Patfield SA; Testa S; Paglialonga F; Picicco D; Caprioli A; Scavia G; Morabito S; Ardissino G
    Thromb Haemost; 2020 Jan; 120(1):107-120. PubMed ID: 31858520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin.
    Zanchi C; Zoja C; Morigi M; Valsecchi F; Liu XY; Rottoli D; Locatelli M; Buelli S; Pezzotta A; Mapelli P; Geelen J; Remuzzi G; Hawiger J
    J Immunol; 2008 Jul; 181(2):1460-9. PubMed ID: 18606701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral immune response to Shiga Toxin 2 (Stx2) among Brazilian urban children with hemolytic uremic syndrome and healthy controls.
    Guirro M; Piazza RM; de Souza RL; Guth BE
    BMC Infect Dis; 2014 Jun; 14():320. PubMed ID: 24919599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Shiga toxin 2 antibodies in enterohemorrhagic Escherichia coli O104:H4 infected patients may predict hemolytic uremic syndrome.
    Dammermann W; Mihajlov V; Middendorf B; Mellmann A; Karch H; Lüth S; Ullrich S
    J Gastroenterol Hepatol; 2018 Jul; 33(7):1353-1356. PubMed ID: 29280264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.